High Grade Glioma

P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra

In some cell lines, the fiber modification F5RGD10(2C) or verapamil treatment further improves actual spread efficiency. Nelfinavir inhibits spread and plaque formation of oncolytic adenoviruses with the 19KSS-iLQ125Ter modifications, irrespective of adenovirus death protein (ADP) expression...We identified an insertion site downstream of the L3-23K region that supports relatively high hPH20 activity while preserving the enhanced oncolytic potency of the virus. Combining 19KSS-iLQ125Ter with hPH20 expression may potentially improve therapeutic benefit in glioma.

P2, N=45, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

P1/2, N=40, Not yet recruiting, National Institute of Neurological Disorders and Stroke (NINDS)

P1, N=10, Recruiting, Case Comprehensive Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2026

Investigated viral platforms included herpes simplex virus type 1 (G207, HSV1716), adenovirus (DNX-2401, ICOVIR-5, Ad-TD-nsIL12), T-VEC (HSV-1), poliovirus (PVSRIPO), Seneca Valley virus, and reovirus. Overall risk of bias was moderate, while the certainty of evidence was rated as low for safety outcomes and very low for efficacy. These findings indicate that oncolytic virotherapy is safe, feasible, and biologically active in children with malignant brain and solid tumors, and that preliminary survival signals and consistent immune activation support further investigation through larger, multicenter randomized trials and combination strategies with radiotherapy or immune checkpoint inhibitors.

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

Sting activation was visualized longitudinally using 3'-deoxy-3'-[18F]-fluorothymidine ([18F]-FLT) PET, which peaked 72-96 hours after 8803 administration. In summary, 8803 combined with RT triggers distinctive antiglioma immune reactivity, facilitates BBB opening, and warrants consideration for up-front clinical trials in glioblastoma, where treatment effects can be monitored using [18F]-FLT PET imaging.

This approach may facilitate personalized treatment planning and address limitations of invasive tissue-based diagnostics. Further validation with multi-center data is warranted to enhance clinical applicability.

The co-occurrence of MSH2 splicing disruption and MSH6 frameshift mutation synergistically exacerbated genomic instability, highlighting a potential mechanism for LS-driven gliomagenesis. This case underscores the importance of genetic screening in young-onset or familial GBM patients, advocates for integrating molecular profiling into therapeutic decision-making, and expands the understanding of LS-associated CNS tumorigenesis.

All patients underwent maximal safe resection followed by adjuvant radiotherapy and concurrent plus maintenance temozolomide (TMZ)...However, in IDHwt patients, unmethylated status was associated with worse OS (HR 3.66, p < 0.001) compared to methylated (HR 2.16, p = 0.009). These findings reaffirm the prognostic significance of IDH mutations and MGMTp methylation in GBM, underscoring their relevance in clinical stratification and treatment planning.

Doses needed to eliminate OLIG2 expression in vitro varied from 0.3 to >1 µM in pGBM cells. In summary, our data showed that orally administered CT-179 penetrated the blood-brain barrier (BBB) and exhibited potential for inhibiting pGBM growth when combined with XRT.